In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Implantation of ICD and CRT-D in the elderly population: will it be a limiting factor?

Session ICD indications in 2017

Speaker Ines Aguiar Ricardo

Event : ESC Congress 2017

  • Topic : arrhythmias and device therapy
  • Sub-topic : Implantable Cardioverter / Defibrillator
  • Session type : Advances in Science

Authors : I Aguiar-Ricardo (Lisbon,PT), N Cortez-Dias (Lisbon,PT), P Marques (Lisbon,PT), A Magalhaes (Lisbon,PT), I Goncalves (Lisbon,PT), J Agostinho (Lisbon,PT), G Lima Da Silva (Lisbon,PT), T Guimaraes (Lisbon,PT), I Santos (Lisbon,PT), AR Francisco (Lisbon,PT), A Bernardes (Lisbon,PT), HC Costa (Lisbon,PT), L Carpinteiro (Lisbon,PT), J Fauto Pinto (Lisbon,PT), J De Sousa (Lisbon,PT)

I. Aguiar-Ricardo1 , N. Cortez-Dias1 , P. Marques1 , A. Magalhaes1 , I. Goncalves1 , J. Agostinho1 , G. Lima Da Silva1 , T. Guimaraes1 , I. Santos1 , A.R. Francisco1 , A. Bernardes1 , H.C. Costa1 , L. Carpinteiro1 , J. Fauto Pinto1 , J. De Sousa1 , 1Hospital Universitário de Santa Maria/CHLN, CAML, CCUL,Faculdade de Medicina, Universidade de Lisboa, Cardiology - Lisbon - Portugal ,

European Heart Journal ( 2017 ) 38 ( Supplement ), 619-620

Introduction: Implantable cardioverter defibrillator (ICD) and cardiac resynchronization (CRT-D) implantation in elderly patients is effective in preventing sudden death, although limited by the natural shorter life expectancy. The different device brands present very variable survival estimates and it has been discussed the availability of less expensive, less longevity generators for the elderly population.

Purpose: To determine if the expected survival rate in the elderly patient population (≥75 years) should influence the selection of the desired longevity of the devices.

Methods: A retrospective single-center study of consecutive patients who underwent implantation of ICD or CRT-D after November 1995. The mean survival of patients undergoing 1st implant or generator replacement at an advanced age (≥75 years) was evaluated and compared to the effective longevity of the generators. Cumulative survival analyzes using the Kaplan Meier method were used.

Results: A total of 1312 cardiac devices were implanted, of which 163 generators in elderly patients (53% CDI and 47% CRT-D). Of these, 77% corresponded to the 1st implant.

The median survival after implantation of the elderly patients was 6.8 years, not differing according to the type of device (Log-rank P = NS). The median longevity of CDI generators was 6.9 years, in line with the expected survival of elderly patients. Conversely, the median CRT-D longevity was 5.8 years, lower than the average survival of the elderly. For this reason, 21% of these CRT-D carriers were subsequently subjected to generator replacement, due to battery exhaustion.

Conclusion: The effective longevity of ICDs is in agreement with an expected survival of elderly patients, for which it will not make sense to provide generators of shortened longevity for this population. The effective longevity of the CRTs is lower than the survival expectancy of the treatments, so that, paradoxically, generators with increased longevity should be favored.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are